Stock Report

All about this stock under one free report Last Updated: 29-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Supriya Lifescience Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: SUPRIYA | BSE: 543434

₹804.15

up-down-arrow ₹27.80 (3.58%)

As on 28-Aug-2026IST

Market cap

info icon

₹6,469 Cr

Revenue (TTM)

info icon

₹873 Cr

P/E Ratio

info icon

32.6

P/B Ratio

info icon

5.3

Div. Yield

info icon

0.1 %

Edit peer-selector-edit
Supriya Lifescience Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Market cap (₹ Cr)
 6,469 21,501 19,125 18,253 17,766
Revenue (₹ Cr)
 873 2,570 2,287 3,230 2,432
Net Profit (₹ Cr)
 198.37 735.15 678.07 666.92 169.62
Net Margin (%)
 22.44 26.88 28.10 20.60 6.90
RoE (%)
 17.43 19.16 19.73 18.75 20.76
Price to Earnings
 32.61 29.25 28.74 28.35 104.74
Price-To-Book
 5.29 4.88 5.08 4.51 19.65

Income Statement (₹ Cr)

Supriya Lifescience Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Operating Revenue arrow
872.55 2,569.77 2,287.33 3,229.67 2,432.06
Total Income arrow
884.01 2,735.39 2,413.29 3,237.12 2,458.54
Total Expenditure arrow
582.74 1,628.14 1,490.75 2,090.06 2,202.20
EBITDA arrow
289.80 941.63 796.58 1,139.61 229.86
Depreciation arrow
30.90 57.58 78.10 281.06 17.24
EBIT arrow
258.91 884.05 718.48 858.55 212.62
Interest arrow
1.75 7.69 0.88 190.64 5.72
Other Income arrow
11.46 165.62 125.96 7.45 26.48
Exceptional Items arrow
-0.46 -49.16 0.00 -17.24 -5.13
Profit before Tax arrow
268.16 992.82 843.56 658.12 228.25
Provision for Tax arrow
69.79 257.67 165.49 -8.80 58.63
Profit after Tax arrow
198.37 735.15 678.07 666.92 169.62

Liabilities (₹ Cr)

Supriya Lifescience Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Shareholder's Funds arrow
1,197.73 4,202.90 3,586.42 3,902.67 872.79
Minority Interest arrow
0.00 0.00 -12.71 -21.81 0.00
Non-Current Liabilities arrow
38.33 91.50 28.74 1,392.75 134.50
Current Liabilities arrow
121.04 627.48 385.94 2,077.10 981.81
Total Liabilities arrow
1,117.35 4,911.11 3,207.85 6,862.28 1,879.19

Assets (₹ Cr)

Supriya Lifescience Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Non-Current Assets arrow
818.70 770.28 1,291.22 5,617.77 42.47
Current Assets arrow
532.30 3,803.22 2,585.66 1,539.85 1,739.93
Total Assets arrow
1,117.35 4,911.11 3,207.85 6,862.28 1,879.19
Total Debt* arrow
0.00 2.50 0.55 2,421.66 0.00
Net Current Assets arrow
411.26 3,175.74 2,199.72 -537.25 758.12
Contingent Liabilities arrow
4.17 363.79 0.64 64.29 98.41

Cashflow (₹ Cr)

Supriya Lifescience Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Cash From Operating Activities arrow
164.68 659.75 432.37 1,065.01 65.36
Cash Flow from Investing Activities arrow
-152.24 -71.34 -334.73 -79.97 30.80
Cash from Financing Activities arrow
-8.23 -205.34 -38.32 -881.32 -65.59
Net Cash Inflow / Outflow arrow
4.20 383.07 59.32 103.72 30.57

Ratios

Profitability Ratios

 Supriya Lifescience Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
ROCE (%) arrow
27.63 26.21 26.22 13.59 21.29
ROE (%) arrow
17.43 19.16 19.73 18.75 20.76
ROA (%) arrow
16.07 14.95 18.69 9.26 9.67
EBIT Margin (%) arrow
29.67 34.40 31.41 26.58 8.74
Net Margin (%) arrow
22.44 26.88 28.10 20.60 6.90
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Supriya Lifescience Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Revenue Growth (%) arrow
28.14 10.69 15.01 9.59 31.10
EBIT Growth (%) arrow
13.70 24.14 18.45 16.84 -12.99
Net Profit Growth (%) arrow
11.38 -9.09 19.61 62.68 -7.49
EPS Growth (%) arrow
11.57 14.40 17.73 67.41 -18.33
Book Value Growth (%) arrow
22.25 17.30 23.77 10.19 7.70

Valuation Ratios

 Supriya Lifescience Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Price / Earnings arrow
32.55 27.87 28.74 27.66 102.37
Price / Book Value arrow
5.29 4.88 5.08 4.51 19.65
Dividend Yield (%) arrow
0.12 1.60 0.16 0.55 0.51
EV/EBITDA arrow
22.05 19.53 22.88 17.94 75.34
Market Cap (₹ Cr) arrow
5,903.96 18,318.10 15,219.80 19,292.77 21,515.93

Solvency Ratios

 Supriya Lifescience Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Debt to Equity arrow
0.00 0.00 0.00 0.24 0.00
Short term debt to equity ratio arrow
-- 0.00 0.00 0.14 --
Current Ratio arrow
4.40 6.06 6.70 0.74 1.77
Quick Ratio arrow
3.08 5.31 5.59 0.53 0.73
Interest Coverage arrow
154.15 130.11 959.59 4.45 40.90

Operating Efficiency Ratios

 Supriya Lifescience Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Debtors to sales (%) arrow
25.15 7.07 36.10 21.07 8.79
Asset Turnover arrow
0.71 0.52 0.63 0.45 1.39
Receivable days arrow
57.43 29.10 110.70 54.07 35.81
Inventory Days arrow
47.52 69.53 65.86 32.16 82.25
Payable days arrow
115.90 76.77 105.88 140.91 124.39
Cash Conversion Cycle arrow
-10.96 21.86 70.68 -54.68 -6.33
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...